Nu-Med Plus Inc. (NUMD:OTC.MKTS) announced in a news release its newly engineered nitric oxide delivery unit will "receive its first clinical unit prototype and begin testing to verify design parameters."
"The clinical unit multiplies the number of markets Nu-Med Plus is able to serve with our technology," Nu-Med Plus CEO Jeff Robins said in the release.
The company developed this clinical inhaled nitric oxide product for healthcare providers to be able to provide in-office treatment options for various conditions and diseases, including high blood pressure, chronic obstructive pulmonary disease and acute respiratory distress syndrome. This new unit is smaller, to simplify storage, and smarter, featuring a touchscreen for easy use and single-dose control.
Nu-Med is currently in the process of seeking approval from the FDA for three of its nitric oxide delivery consoles: this clinical unit, a fixed hospital unit and a portable unit.[NLINSERT]
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.